Attention CF Patients With Persistent MRSA Lung Infection:
A Phase 2 clinical trial to evaluate the safety and efficacy of an inhaled anti-MRSA antibiotic is enrolling now.
MRSA + CF
The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently at 27% in the U.S. Recent publications indicate that chronic MRSA lung infection is associated with more hospitalizations, faster decline in lung function and reduced life expectancy.
Vancomycin is one of the most commonly used drugs for the treatment of MRSA infection, but is only available as an intravenous formulation. Currently there is no approved inhaled therapy for MRSA, despite the established practice in CF patients of delivering antimicrobial medications directly to the lungs. To address this issue, Savara Pharmaceuticals is developing an inhaled, dry-powder formulation of vancomycin, called AeroVanc, for persistent MRSA lung infection in CF patients.
AeroVanc Phase 2 Clinical Trial
Savara Pharmaceuticals is currently enrolling patients to evaluate the effectiveness, safety and pharmacokinetics of AeroVanc compared to placebo in subjects with CF and chronic MRSA lung infection. Enrollment for a phase II, randomized, placebo-controlled, 80-patient study is underway at 40 sites across the U.S.
Interested in enrolling?
At a basic level, patients interested in participating in the study must have a diagnosis of cystic fibrosis, be at least 12 years old and have evidence of persistent MRSA lung infection that is suspected to be causing health consequences.
For a full list of eligibility criteria, and to find a study site near you, please visit the AeroVanc website.